Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Halozyme ( (HALO) ).
On December 4, 2025, Halozyme Therapeutics, Inc. announced the election of James Lang to its Board of Directors, with his term set to end at the company’s annual meeting in 2027. Lang will receive compensation in line with the company’s director compensation program, and his election is not tied to any specific arrangements or related person transactions, indicating a straightforward appointment process.
The most recent analyst rating on (HALO) stock is a Buy with a $71.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. However, technical analysis indicates bearish momentum, and high leverage poses a risk. Strategic corporate events and reasonable valuation provide additional support for the stock’s potential.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing products that enhance the delivery of drugs and fluids. The company is known for its proprietary enzyme-based technology, which is used to improve the absorption and dispersion of biologics and pharmaceuticals.
Average Trading Volume: 2,221,388
Technical Sentiment Signal: Buy
Current Market Cap: $7.45B
Learn more about HALO stock on TipRanks’ Stock Analysis page.